NZ629283A - Novel binding molecules with antitumoral activity - Google Patents
Novel binding molecules with antitumoral activityInfo
- Publication number
- NZ629283A NZ629283A NZ629283A NZ62928313A NZ629283A NZ 629283 A NZ629283 A NZ 629283A NZ 629283 A NZ629283 A NZ 629283A NZ 62928313 A NZ62928313 A NZ 62928313A NZ 629283 A NZ629283 A NZ 629283A
- Authority
- NZ
- New Zealand
- Prior art keywords
- binding
- tumour cells
- antigen expressed
- peptide
- poly
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 210000004881 tumor cell Anatomy 0.000 abstract 4
- -1 PDGF Proteins 0.000 abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 abstract 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- 108010065524 CD52 Antigen Proteins 0.000 abstract 1
- 102000013135 CD52 Antigen Human genes 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 abstract 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 abstract 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 abstract 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 abstract 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 abstract 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 abstract 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Environmental Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12159938 | 2012-03-16 | ||
| PCT/EP2013/054768 WO2013135588A1 (en) | 2012-03-16 | 2013-03-08 | Novel binding molecules with antitumoral activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ629283A true NZ629283A (en) | 2016-04-29 |
Family
ID=47844323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ629283A NZ629283A (en) | 2012-03-16 | 2013-03-08 | Novel binding molecules with antitumoral activity |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9593314B2 (OSRAM) |
| EP (1) | EP2825197B1 (OSRAM) |
| JP (1) | JP6325463B2 (OSRAM) |
| KR (1) | KR20140135251A (OSRAM) |
| CN (1) | CN104284675B (OSRAM) |
| AU (1) | AU2013231488B2 (OSRAM) |
| BR (1) | BR112014022932A2 (OSRAM) |
| CA (1) | CA2865597A1 (OSRAM) |
| MX (1) | MX354717B (OSRAM) |
| NZ (1) | NZ629283A (OSRAM) |
| RU (1) | RU2627185C1 (OSRAM) |
| WO (1) | WO2013135588A1 (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9956276B2 (en) | 2012-01-19 | 2018-05-01 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| EP2752426A1 (en) * | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
| EP3074424B1 (en) | 2013-11-27 | 2025-02-12 | Zymeworks BC Inc. | Bispecific antigen-binding constructs targeting her2 |
| JP2017504325A (ja) * | 2014-01-14 | 2017-02-09 | インテグレイテッド バイオセラピューティクス，インコーポレイテッド | バクテリオシンの細胞壁ターゲティングドメインを用いた細菌感染部位への免疫学的機能のターゲティング方法 |
| WO2015131035A1 (en) | 2014-02-27 | 2015-09-03 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods |
| CN106211782B (zh) * | 2014-03-17 | 2021-01-15 | 田边三菱制药株式会社 | 抗体-fynomer缀合物 |
| EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
| EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| WO2016007504A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016082044A1 (en) | 2014-11-27 | 2016-06-02 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
| JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物 |
| KR20180025894A (ko) | 2015-06-11 | 2018-03-09 | 라이세라 코퍼레이션 | Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료 |
| FI126633B (en) | 2015-07-10 | 2017-03-15 | Next Biomed Therapies Oy | Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1) |
| WO2017120576A1 (en) * | 2016-01-07 | 2017-07-13 | Duke University | Cancer vaccines and methods of delivery |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| KR102532256B1 (ko) | 2016-11-21 | 2023-05-12 | 쿠레아브 게엠베하 | 항-gp73 항체 및 면역접합체 |
| US10722589B2 (en) | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
| US20190100587A1 (en) | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| CN111886247A (zh) | 2018-01-05 | 2020-11-03 | Ac免疫有限公司 | 错折叠tdp-43结合分子 |
| JP7350756B2 (ja) | 2018-02-14 | 2023-09-26 | アバ セラピューティクス アーゲー | 抗ヒトｐｄ－ｌ２抗体 |
| RU2018111298A (ru) * | 2018-03-29 | 2019-10-01 | Закрытое Акционерное Общество "Биокад" | Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека |
| CA3133909A1 (en) | 2019-04-18 | 2020-10-22 | Elpida TSIKA | Novel molecules for therapy and diagnosis |
| JP2022533432A (ja) | 2019-05-23 | 2022-07-22 | エイシー イミューン ソシエテ アノニム | 抗ｔｄｐ－４３結合分子およびその使用 |
| WO2020254540A1 (en) | 2019-06-18 | 2020-12-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as his-tagged proteins via metal complex reagents |
| EP4061830A1 (en) | 2019-11-20 | 2022-09-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Archaeal peptide recombinase - a novel peptide ligating enzyme |
| WO2021116337A1 (en) | 2019-12-11 | 2021-06-17 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| AR123165A1 (es) | 2020-08-07 | 2022-11-02 | Hoffmann La Roche | Un método para la producción de composiciones protéicas |
| US20230322908A1 (en) | 2020-08-14 | 2023-10-12 | Ac Immune Sa | Humanized Anti-TDP-43 Binding Molecules and Uses Thereof |
| WO2022043517A2 (en) | 2020-08-27 | 2022-03-03 | Cureab Gmbh | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
| WO2022079297A1 (en) | 2020-10-16 | 2022-04-21 | Ac Immune Sa | Antibodies binding to alpha-synuclein for therapy and diagnosis |
| US20250223376A1 (en) | 2021-09-20 | 2025-07-10 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| MX2024005876A (es) | 2021-11-16 | 2024-05-29 | Ac Immune Sa | Moleculas novedosas para terapias y diagnostico. |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| AU2023221539A1 (en) | 2022-02-16 | 2024-08-22 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
| KR20250004705A (ko) | 2022-04-08 | 2025-01-08 | 에이씨 이뮨 에스에이 | 항-tdp-43 결합 분자 |
| US20250295809A1 (en) | 2022-05-13 | 2025-09-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2024184494A1 (en) | 2023-03-08 | 2024-09-12 | Ac Immune Sa | Anti-tdp-43 binding molecules and uses thereof |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025221728A2 (en) | 2024-04-15 | 2025-10-23 | Janssen Biotech, Inc. | Ltbr binding molecules and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184205B1 (en) | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| KR20190126461A (ko) * | 2004-07-22 | 2019-11-11 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| BRPI0515589A (pt) | 2004-09-02 | 2008-07-29 | Genentech Inc | polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit |
| US9513296B2 (en) | 2006-08-21 | 2016-12-06 | Eidgenoessische Technische Hochschule Zurich | Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase |
| EP1892248A1 (en) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| US20090155275A1 (en) | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| NZ584514A (en) | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| WO2011020033A2 (en) | 2009-08-13 | 2011-02-17 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
| EP2470556B1 (en) | 2009-08-27 | 2018-05-30 | Covagen AG | Il-17 binding compounds and medical uses thereof |
| JP6184695B2 (ja) * | 2009-12-04 | 2017-08-23 | ジェネンテック， インコーポレイテッド | 多重特異性抗体、抗体アナログ、組成物、及び方法 |
| JP5667207B2 (ja) * | 2009-12-14 | 2015-02-12 | シル プロテインズ ゲーエムベーハーＳｃｉｌ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | リガンドへの結合能を有するヘテロ多量体修飾ユビキチンタンパク質の同定方法 |
| NZ604003A (en) * | 2010-05-27 | 2015-04-24 | Genmab As | Monoclonal antibodies against her2 |
| WO2012009705A1 (en) * | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
-
2013
- 2013-03-08 EP EP13708424.0A patent/EP2825197B1/en not_active Not-in-force
- 2013-03-08 KR KR1020147029084A patent/KR20140135251A/ko not_active Ceased
- 2013-03-08 NZ NZ629283A patent/NZ629283A/en not_active IP Right Cessation
- 2013-03-08 BR BR112014022932A patent/BR112014022932A2/pt not_active Application Discontinuation
- 2013-03-08 CA CA2865597A patent/CA2865597A1/en not_active Abandoned
- 2013-03-08 MX MX2014011066A patent/MX354717B/es active IP Right Grant
- 2013-03-08 CN CN201380014237.9A patent/CN104284675B/zh not_active Expired - Fee Related
- 2013-03-08 JP JP2014561381A patent/JP6325463B2/ja not_active Expired - Fee Related
- 2013-03-08 WO PCT/EP2013/054768 patent/WO2013135588A1/en not_active Ceased
- 2013-03-08 US US14/385,729 patent/US9593314B2/en not_active Expired - Fee Related
- 2013-03-08 AU AU2013231488A patent/AU2013231488B2/en not_active Ceased
- 2013-03-08 RU RU2014141598A patent/RU2627185C1/ru not_active IP Right Cessation
-
2017
- 2017-03-09 US US15/454,769 patent/US20170281768A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170281768A1 (en) | 2017-10-05 |
| MX354717B (es) | 2018-03-16 |
| JP6325463B2 (ja) | 2018-05-16 |
| CN104284675A (zh) | 2015-01-14 |
| JP2015516801A (ja) | 2015-06-18 |
| EP2825197A1 (en) | 2015-01-21 |
| CN104284675B (zh) | 2017-07-18 |
| CA2865597A1 (en) | 2013-09-19 |
| AU2013231488A1 (en) | 2014-09-18 |
| KR20140135251A (ko) | 2014-11-25 |
| WO2013135588A1 (en) | 2013-09-19 |
| AU2013231488B2 (en) | 2017-12-07 |
| US9593314B2 (en) | 2017-03-14 |
| RU2627185C1 (ru) | 2017-08-03 |
| EP2825197B1 (en) | 2018-06-06 |
| BR112014022932A2 (pt) | 2017-07-18 |
| US20150047065A1 (en) | 2015-02-12 |
| MX2014011066A (es) | 2015-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ629283A (en) | Novel binding molecules with antitumoral activity | |
| AR118560A2 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
| IL243568B (en) | Conjugation of a biologically active polypeptide monomer and an immunoglobulin fragment fc with a reduction in receptor elimination and a method for its preparation | |
| MX2015004423A (es) | Conjugados del anticuerpo pirrolobenzodiazepina - anti-her2. | |
| MX360851B (es) | Anticuerpo anti-fgfr2. | |
| MX366223B (es) | Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. | |
| CL2018001000A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr. | |
| EA201692047A1 (ru) | Противоопухолевые комбинации, содержащие специфически распознающие cd38 антитела и бортезомиб | |
| MX2018001533A (es) | Receptores de antigeno quimerico con funciones controlables integradas. | |
| PH12015501846A1 (en) | Novel antibody conjugates and uses thereof | |
| EA201591700A1 (ru) | Гибридные белки апелина и их применение | |
| MX2015013203A (es) | Conjugados de anticuerpo - farmaco. | |
| MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
| PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
| MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
| PH12016500781A1 (en) | Novel anti-claudin antibodies and methods of use | |
| MX364326B (es) | Conjugados del anticuerpo pirrolobenzodiazepina - anti-psma. | |
| MX2015011951A (es) | Proteinas de fusion que comprenden partes de union a pdgf y vegf y metodos de uso de las mismas. | |
| EA201490070A1 (ru) | Коантагонисты глюкагонового рецептора/glp-1-рецептора | |
| EP3077051A4 (en) | Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture | |
| UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
| MX2016007369A (es) | Nuevos anticuerpos anti-dpep3 y metodos de uso. | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| PH12015500751A1 (en) | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4 | |
| EA201791203A1 (ru) | ЛЕКАРСТВЕННЫЙ КОНЪЮГАТ АНТИТЕЛА ПРОТИВ с-МЕТ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2018 BY CPA GLOBAL Effective date: 20170203 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2019 BY CPA GLOBAL Effective date: 20180201 |
|
| LAPS | Patent lapsed |